

Satellite Symposia

Session: SAT2 - Janssen-Cilag Satellite Symposium - From Cognition to Behaviour: Covering Ground with Galantamine
Type: Satellite Sessions
Date: Wednesday, September 21, 2005
Time: 17:45 - 19:15
Room: Congress Hall A
Chair: Ingmar Skoog

Welcome and introduction
Ingmar Skoog, Gothenburg, Sweden Symposium

Diagnosis and treatment of AD w/CVD and 'pure' VaD with galantamine: Implications for practice
Erkinjuntti, Timo
Helsinki University Central Hospital, Finland

Galantamine over time: The value of long-term treatment
Burns, Alistair
University of Manchester School of Medicine, United Kingdom

Behavioural outcomes in dementia: Reducing caregiver burden
Monsch, Andreas
University Hospital Basel, Switzerland

Wrap-up
Ingmar Skoog, Sweden

Session: SAT3 - Merz Pharmaceuticals Satellite Symposium - Therapy of Alzheimer's Disease with Memantine: Benefits for the Patient, Caregiver and Society
Type: Satellite Sessions
Date: Thursday, September 22, 2005
Time: 07:00 - 08:30
Chair: Bengt Winblad

Introduction
Bengt Winblad, Sweden

Caring environment for patients with dementia
Sandman, Per Olof
Umea University, Sweden

Memantine treatment of mild to severe AD
Grossberg, George T.
St. Louis University Health Sciences Center, United States

Memantine's effect on behaviour and activities of daily living: benefits for patients and caregivers
Gauthier, Serge
Mc Gill Center for Alzheimer and Aging, Québec, Canada

Panel discussion

Bengt Winblad, Sweden

Session: SAT4 - Jansen-Cilag Satellite Symposium - Conventional Versus Atypical Antipsychotics in Dementia: Evaluating the Past, Defining the Future
Type: Satellite Sessions
Date: Thursday, September 22, 2005
Time: 18:00 – 19:30
Room: Congress Hall A
Chair: George Grossberg, United States

The scope of the problem: Targeting the symptoms
Grossberg, George
St Louis University Medical Center, United States

Current evidence of efficacy: What have we learned?
De Deyn, Peter
Middelheim Ziekenhuis, Belgium

Assessing the risks: Informed choice?
Kurz, Alexander
Technische Universitaet Muenchen, Germany

Special topic: Consequences of movement disorders
Jeste, Dilip
University of California, United States

The debate: Conventional versus atypical antipsychotics in dementia: The future of symptom treatment in dementia

Q&A session

Wrap-up
George Grossberg, United States

Session: SAT5 - Novartis Satellite Symposium - Rapid Decline in Dementia - Predictors, Genetics and Treatment Options
Type: Satellite Sessions
Date: Thursday, September 22, 2005
Time: 18:00-19:30
Room: Congress Hall C
Chair: Serge Gauthier, Canada

Introduction and overview of rapid decline
Serge Gauthier, Canada

Predictors of rapid decline in dementia
Vellas, Bruno
CHU de Toulouse, France

Does rapid decline dementia have a genetic basis?

Gauthier, Serge

MCSA Alzheimer's disease Research Unit, Quebec, Canada

Hallucinations in patients with rapidly declining dementia

Burn, David

University of Newcastle upon Tyne, United Kingdom

Treating rapid decline in dementia - the effects of cholinesterase inhibition

Farlow, Martin R

Indiana University School of Medicine, United States

Q&A

Panel

Chairmans close and conclusions

Serge Gauthier, Canada

Session: SAT7 - Eisai-Pfizer Satellite Symposium - Cholinergic Treatment
Across the Spectrum: Therapeutic Trends in Mild to Severe Dementia
Type: Satellite Sessions
Date: Friday, September 23, 2005
Time: 18:00 - 19:30

Welcome and introduction

Stephen Salloway, United States

Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease

Nordberg, Agneta

Huddinge Hospital, Karolinska Institutet, Sweden

Buying time: management of early dementia

Salloway, Stephen

Butler Hospital and Brown Medical School, United States

Severe Alzheimer's disease: benefits of continuing therapy

Winblad, Bengt

Huddinge Hospital, Karolinska Institutet, Sweden

Panel discussion Q&A

Stephen Salloway, Bengt Winblad, Agneta Nordberg